- Letter to the Editor
- Open Access
Identification and functional analysis of the BIM interactome; new clues on its possible involvement in Epstein–Barr Virus-associated diseases
Journal of Biological Research-Thessaloniki volume 22, Article number: 14 (2015)
Epigenetic deregulation is a common feature in the pathogenesis of Epstein–Barr Virus (EBV)-related lymphomas and carcinomas. Previous studies have demonstrated a strong association between EBV latency in B-cells and epigenetic silencing of the tumor suppressor gene BIM. This study aimed to the construction and functional analysis of the BIM interactome in order to identify novel host genes that may be targeted by EBV. Fifty-nine unique interactors were found to compose the BIM gene network. Ontological analysis at the pathway level highlighted infectious diseases along with neuropathologies. These results underline the possible interplay between the BIM interactome and EBV-associated disorders.
It is well established that the epigenetic interplay between Epstein–Barr Virus (EBV) and the host contributes to the pathogenesis of EBV-related diseases [1, 2]. Previous studies have revealed that EBV latency in B-cells leads to the epigenetic silencing of the BCL2-Like 11 apoptosis facilitator (BIM) [3, 4]. This study presents a bioinformatic analysis towards the identification and functional prediction of BIM interacting partners so as to indicate new, potential host targets of EBV. The gene network of BIM was constructed by interrogating the following three databases: Biogrid (http://thebiogrid.org), String (http://string-db.org) and GeneMania (http://www.genemania.org). The Biogrid database is a repository of genetic and protein–protein interactions that are curated from the primary biomedical literature for all major model organism species . String is a database of known and predicted protein interactions including both direct (physical), and indirect (functional) associations . GeneMania is a prediction server that generates hypotheses about gene function, analyzes gene lists and prioritizes genes for functional assays . Subsequently, the Human Gene Compendium-GeneCards (http://www.genecards.org) was used in order to assess the description of the retrieved genes. GeneCards is an integrated database of human genes that provides concise genomic related information, on all known and predicted human genes . BIM interactors that were found in all three databases were then entered as a list in the GeneCodis3 database (http://genecodis.cnb.csic.es/) for functional enrichment analysis of Gene Ontology (GO) annotations relative to cellular pathways. GeneCodis is a tool for modular and singular enrichment analysis oriented to integrate information from different sources . Annotations selected were KEGG and PANTHER pathways. The p values were obtained through Hypergeometric analysis corrected by the False Discovery Ratio (FDR) method. The option of high confidence/no more than ten interactors was selected in the String database so as to increase the level of certainty.
Fifty-nine unique BIM interactors were identified. Seven of these interactors (MCL1: myeloid cell leukemia 1; BCL2L1: BCL2-like 1; BCL2: B cell CLL/lymphoma 2; DYNLL1: dynein, light chain, LC8-type 1; BCL2L2: BCL2-like 2; MAPK8: mitogen-activated protein kinase 8; BAX: BCL2-associated X protein) appeared in all three databases and were further subjected to functional analysis as the level of confidence for the common genes is much more significant. The modular enrichment analysis identified: (1) pathways related to cancer including apoptosis, (2) pathways related to Amyotrophic Lateral Sclerosis (ALS), and (3) pathways related to other infectious diseases like tuberculosis and toxoplasmosis (Table 1). The singular enrichment analysis of KEGG and PANTHER pathways highlighted: (1) pathways involved in cancer as JAK-STAT and Wnt signalling pathways, (2) pathways related to neurodegenerative disorders [like Huntington’s disease (HD) Parkinson disease (PD), Alzheimer disease (AD) and ALS], (3) pathways involved in infectious diseases like epithelial cell signalling in Escherichia coli infection, Chagas disease, Hepatitis C and prion diseases (results not shown).
EBV is a known oncogenic virus associated with 1 % of cancers worldwide . The interactions of EBV with members of the Bcl-2 family like BAX, BCL2, BCL2L1, BCL2L2 and MCL1 in human tumor cells, have been extensively reviewed in Fu et al. . Thus, the prediction that the BIM interactome is involved in cancer pathways was not surprising. The main finding of this study is the indication that several BIM interactors participate in pathways related to neurodegenerative disorders. In such diseases, like AD, PD, ALS and—to a less extent—HD, many studies have highlighted the importance of the immune system and the involvement of neuroinflammation . It has been suggested that the adaptive immune response to EBV represents the key initiating event in PD . Recently, a study has reported on a high level of octapeptide matching between 7 viruses (including EBV), and human brain antigens that, when altered, have been specifically associated with neuropathologies such as ALS, HD and PD . Another important finding arising from the ontological analysis is the prediction that the BIM interactome participates in pathways associated with other infectious agents. The cooperative contribution of HIV, malaria and EBV in lymphomagenesis has long been established while the possibility of synergy between EBV and Helicobacter pylori in the pathogenesis of gastric carcinomas has recently begun to unfold . Any possible association of EBV with other infectious diseases revealed by the functional analysis remains to be studied.
Cumulatively, by using contemporary bioinformatic tools this study has demonstrated that the BIM regulatory network consists of 59 unique genes that could be targeted by EBV. Furthermore, it has predicted that several BIM interactors have a central role in pathways associated with neurodegenerative disorders and infectious diseases. The BIM interactome warrants further study, in terms of clinical research, with respect to its interplay with EBV.
Amyotrophic Lateral Sclerosis
Niller HH, Szenthe K, Minarovits J. Epstein–Barr virus-host cell interactions: an epigenetic dialog? Front Genet. 2014;5:367. doi:10.3389/fgene.2014.00367.
Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol. 2014;26:22–9.
Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumor-suppressor BIM: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene. 2008;27:421–33.
Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein–Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumor suppressor gene BIM. PLoS Pathog. 2009;5:e1000492.
Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res. 2013;41:D816–23.
Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39:D561–8.
Zuberi K, Franz M, Rodriquez H, Montojo J, Lopes CT, Bader GD, et al. GeneMANIA prediction server 2013 update. Nucleic Acids Res. 2013;41:W115–22.
Safran M, Chalifa-Caspi V, Shmueli O, Olender T, Lapidot M, Rosen N, et al. Human gene-centric databases at the Weizmann Institute of Science: GeneCards, UDB, CroW 21 and HORDE. Nucleic Acids Res. 2003;31:142–6.
Nogales-Cadenas R, Carmona-Saez P, Vasquez M, Vicente C, Yang X, Tirado F, et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 2009;37:W317–22.
Houldcroft CJ, Kellam P. Host genetics of Epstein–Barr virus infection, latency and disease. Rev Med Virol. 2015;25:71–84.
Fu Q, He C, Mao ZR. Epstein–Barr interactions with the Bcl-2 protein family and apoptosis in human tumor cells. J Zhejiang Univ Sci B. 2013;14:8–24.
Ellrichmann G, Reick C, Saft C, Linker RA. The role of the immune system in Huntington’s disease. Clin Dev Immunol. 2013;2013:541259. doi:10.1155/2013/541259.
Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM. Hypothesis: a role for EBV-induced molecular mimicry in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:685–94.
Lucchese G, Kanduc D. Single amino acid repeats connect viruses to neurodegeneration. Curr Drug Discov Technol. 2014;11:214–9.
Rickinson AB. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol. 2014;26:99–115.
ER designed the research, analyzed and interpreted the data. DK revised the paper critically. Both authors read and approved the final manuscript.
We wish to thank Dr SG Zarogiannis for his valuable and constructive recommendations on this study.
The authors declare that they have no competing interests.